Real Assets

Real Assets

We build future energy systems and resilient infrastructure, backing emerging opportunities in technology, land and water.

Latest news

News

Foresight invests £2.5 million into Bloemteknik

Latest news

News

Foresight invests £2.5 million into Bloemteknik

Featured insight

Insights

Are EVs really rolling backwards?

Skip to main content
Engagement case study

Steris

Q1 2023 Engagement case study: product impact

Steris provides a variety of products and services to the healthcare industry including to hospitals, medical device manufacturers, pharmaceutical companies and biotechnology businesses, as well as food safety and industrial markets. The company’s main areas of activity are providing hygiene, sterilisation and anti-microbial treatment services to these end markets in order to ensure a safe and hygienic operating environment.


Objective

Strengthen our understanding of the positive impact associated with Steris’ products and services.

Background/issue

We have been speaking to investee companies as part of a project to further strengthen our understanding of the positive impact associated with their products and services. Additional insights allow us to build a stronger ‘impact investment case’ for each of our stocks helping us to deepen our analysis and refine the impact score we give to our companies.

Actions

Whilst undertaking a review of the research within Steris’ Impact Engine, we identified areas that would benefit from additional detail, including quantifying the extent to which human error influences the efficacy of sterilisation and reprocessing of medical devices, the role of Steris’s products and services in enabling the positive outcomes, and the uniqueness of the company’s contribution.

Outcomes

Successful/Milestone 2: We had a productive call with our contact in Investor Relations who provided additional detail for our impact analysis. For example, we discussed the role of human error as the most significant factor influencing the efficacy of Steris’s equipment and the measures taken by the company to reduce the risk of it occurring. This includes reducing the number of decision and touch points for reprocessing staff by increasing automation. The company was, however, unable to quantify the proportion of processes that have been automated. We also discussed Steris’ in-house training provided for the reprocessing operatives working within its outsourcing team and the technologies that it uses to ensure that processes run correctly.

In terms of other factors or services influencing the efficacy of the sterilisation process, Steris was keen to point out that hospital-acquired infections do not typically come from equipment but, instead, mostly from poor hand hygiene or improper cleaning of the operating room though the company did not have any data on this. Steris had previously made efforts to offer sterilisation for touchpoint items like blood pressure cuffs, for example, through the use of hydrogen peroxide chambers, though, this was not taken up by the industry because it slows the turnover of the equipment. 

This information has been helpful for adding additional detail in understanding the positive impact of Steris’s products, however it did not change any of the underlying scores within our impact analysis.

News & Insights

You have viewed 0 of 0

Important information


Foresight Group LLP does not offer legal, tax, financial or investment advice and the information on this website should not be construed as such. We recommend investors seek advice from a regulated financial adviser. The opportunity described in this document may not be suitable for all investors. Any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice.

Foresight Group LLP acts as investment manager and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 198020 and has its registered office at The Shard, 32 London Bridge Street, London SE1 9SG.

OEICs

An investment in FP Sustainable Future Themes Fund, FP Foresight Global Real Infrastructure Fund, FP Sustainable Real Estate Securities Fund, FP UK Infrastructure Income Fund or FP WHEB Sustainability Impact Fund and Liontrust Diversified Real Assets Fund (together the “Funds”) should be considered a long-term investment that may be higher risk. Portfolio holdings are subject to change without notice.

The Authorised Corporate Directors FundRock Partners Limited (registered office at Hamilton Centre, Rodney Way, Chelmsford, England, CM1 3BY) and Liontrust Investment Partners LLP (registered office 2 Savoy Court, London WC2R 0EZ), are authorised and regulated by the Financial Conduct Authority with Firm Reference Numbers 469278 and 518552 respectively. The Funds are incorporated in England and Wales.

ICAVs

An investment in the WHEB Sustainable Impact Fund and the WHEB Environmental Impact Fund (together the “Funds”) should be considered a longer-term investment that may be higher risk. Portfolio holdings are subject to change without notice.

The Manager of the Funds is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at Airport Center Building, 5, Heienhaff, L-1736 Senningerberg, Luxembourg.

We respect your privacy and are committed to protecting your personal data. If you would like to find out more about the measures, we take in processing your personal information, please refer to our privacy policy, which can be found at http://www.foresight.group/privacy-policy.